Experimental Neurology, Oct, 2014, Vol.260, p.56(13)
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.expneurol.2013.01.027 Byline: Fredrik J. Swartling, Sara Bolin, Joanna J. Phillips, Anders I. Persson Keywords: Brain tumor; Progenitor; Neural stem cell; Glioma; Medulloblastoma; Reprogramming; miRNA Abstract: Brain tumors have frequently been associated with a neural stem cell (NSC) origin and contain stem-like tumor cells, so-called brain tumor stem cells (BTSCs) that share many features with normal NSCs. A stem cell state of BTSCs confers resistance to radiotherapy and treatment with alkylating agents. It is also a hallmark of aggressive brain tumors and is maintained by transcriptional networks that are also active in embryonic stem cells. Advances in reprogramming of somatic cells into induced pluripotent stem (iPS) cells have further identified genes that drive stemness. In this review, we will highlight the possible drivers of stemness in medulloblastoma and glioma, the most frequent types of primary malignant brain cancer in children and adults, respectively. Signals that drive expansion of developmentally defined neural precursor cells are also active in corresponding brain tumors. Transcriptomal subgroups of human medulloblastoma and glioma match features of NSCs but also more restricted progenitors. Lessons from genetically-engineered mouse (GEM) models show that temporally and regionally defined NSCs can give rise to distinct subgroups of medulloblastoma and glioma. We will further discuss how acquisition of stem cell features may drive brain tumorigenesis from a non-NSC origin. Genetic alterations, signaling pathways, and therapy-induced changes in the tumor microenvironment can drive reprogramming networks and induce stemness in brain tumors. Finally, we propose a model where dysregulation of microRNAs (miRNAs) that normally provide barriers against reprogramming plays an integral role in promoting stemness in brain tumors. Article History: Received 25 October 2012; Revised 19 January 2013; Accepted 24 January 2013
Gliomas -- Analysis ; Brain Tumors -- Analysis ; Embryonic Stem Cells -- Analysis
Cengage Learning, Inc.